Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Operating Income Loss of -$648.13 million for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -35.3% in Operating Income Loss from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$18.34 million | Q2 2020: -$18.22 million | Q3 2020: -$22.47 million | Q1 2021: -$30.48 million | Q2 2021: -$40.93 million | Q3 2021: -$46.40 million | Q1 2022: -$55.98 million | Q2 2022: -$66.19 million | Q3 2022: -$62.57 million | Q1 2023: -$69.87 million | Q2 2023: -$81.72 million | Q3 2023: -$99.55 million | Q1 2024: -$96.34 million | Q2 2024: -$100.54 million | Q3 2024: -$98.35 million | Q1 2025: -$191.37 million | Q2 2025: -$176.23 million | Q3 2025: -$172.20 million.
- Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 938.0%.
- Historical annual values: Fiscal year 2025: -$648.13 million | Fiscal year 2024: -$479.00 million | Fiscal year 2023: -$350.06 million | Fiscal year 2022: -$245.73 million | Fiscal year 2021: -$182.78 million | Fiscal year 2020: -$84.62 million | Fiscal year 2019: -$62.44 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: